A

Alpha Cognition Inc
OTC:ACOGF

Watchlist Manager
Alpha Cognition Inc
OTC:ACOGF
Watchlist
Price: 6.41 USD -2.14% Market Closed
Market Cap: 961m USD

Relative Value

ACOGF doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of ACOGF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACOGF Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Multiples Across Competitors

ACOGF Competitors Multiples
Alpha Cognition Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Alpha Cognition Inc
OTC:ACOGF
9.9m USD 0 -0.4 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 960 685.5 -161 410.1 -167 132.1 -165 224.9
US
Abbvie Inc
NYSE:ABBV
385.5B USD 6.5 164.2 16 22.7
US
Amgen Inc
NASDAQ:AMGN
186.7B USD 5.2 26.7 19 19
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD 5.6 20.1 13.5 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD 10.1 32.3 23.7 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 074.4 -529.3 -676 -657.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
87B AUD 3.8 19.6 8.9 11.1
NL
argenx SE
XBRU:ARGX
42.8B EUR 14 32.9 66.6 68.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD 15.2 1 119.3 150.9 183
P/S Multiple
Revenue Growth P/S to Growth
CA
A
Alpha Cognition Inc
OTC:ACOGF
Average P/S: 3 396 282.6
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 960 685.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.6
4%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 074.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
CA
A
Alpha Cognition Inc
OTC:ACOGF
Average P/E: 179
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 410.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
164.2
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
20.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
10%
1.7
AU
CSL Ltd
ASX:CSL
19.6
11%
1.8
NL
argenx SE
XBRU:ARGX
32.9
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 119.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
A
Alpha Cognition Inc
OTC:ACOGF
Average EV/EBITDA: 39.4
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 132.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
19
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -676 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
8.9
8%
1.1
NL
argenx SE
XBRU:ARGX
66.6
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
150.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
A
Alpha Cognition Inc
OTC:ACOGF
Average EV/EBIT: 45.2
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 224.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19
20%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -657.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
11.1
11%
1
NL
argenx SE
XBRU:ARGX
68.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
183
N/A N/A